Immunotherapy and BRAF-Targeted Therapy Fill Expanded Roles Across Melanoma
Source: Onclive, October 2022
Immunotherapy and targeted therapy combinations containing BRAF and MEK inhibitors have carved out roles in different settings of melanoma, which has given clinicians different options for treatment sequencing, according to faculty from an OncLive® Institutional Perspectives in Cancer webinar on skin cancer.
The event, chaired by Hussein A. Tawbi, MD, PhD, professor, deputy chair, director of Personalized Cancer Therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, covered updates in immunotherapy and targeted therapy for melanoma, including the optimal settings for each treatment type.
Tawbi was joined by:
- Michael A. Davies, MD, PhD, professor, chairman, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center
- Michael K. Wong, MD, PhD, professor, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center
- Sapna Patel, MD, medical oncologist, associate professor, director, Uveal Melanoma Program, Melanoma Fellowship Program, The University of Texas MD Anderson Cancer Center